Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Kelly reflects on a major advance in obesity treatment and highlights a memorable day for diabetes at the Major League Baseball Hall of Fame.
On June 27, the FDA approved Arena Pharmaceutical’s weight-loss drug Belviq (lorcaserin), the first weight-loss drug to be approved in the US in 13 years. Belviq is...
Kelly reflects on some changes here at diaTribe and in the world of diabetes and obesity.
Two well-known endocrinologists debated the merits of inhaled insulin in the February edition of Diabetes Care.
Does how often you eat make your blood glucose worse? CDE Gary Scheiner explains…
Several months after an FDA advisory committee delivered an overwhelmingly positive vote (20-2) in favor of approving Vivus’ Qnexa for the treatment of obesity, the...
Want faster acting insulin? CDE Gary Scheiner shows you some options with five innovative tips that you may want to consider…
While Lantus (Sanofi’s insulin glargine) is the current standard for basal insulins, companies are still investing significant efforts to develop even better long-acting...
As we have previously written, Vivus’ weight loss drug Qnexa is up for approval in the US in April of this year. Encouragingly, Vivus announced recently that, if...
Kerri Morrone Sparling reflects on the true meaning of ‘need’ in the global diabetes community…
On January 27, the Food and Drug Administration (FDA) granted approval to Bydureon, a new drug for type 2 diabetes that is injected once a week. Approved last year in...
What are going to be the big headlines for 2012? What will be the impact of Bydureon, the latest once-weekly drug for people with type 2 diabetes?
Over the past several years, the use of GLP-1 drugs (such as Byetta and Victoza) together with basal insulins (such as Lantus and Levemir) as a treatment for type 2...
In October, Novo Nordisk announced that it had submitted its two new “next-generation” insulin products for approval in both the US and Europe (and Japan to follow soon...
In late July, pharmacy benefit managers (PBMs) Express Scripts and Medco Health Solutions announced their plans to merge. As background, PBMs process prescriptions for...
If you’ve been following our coverage of Orexigen’s obesity drug, Contrave, you’re likely aware that it has been through a regulatory rollercoaster over the past few...
In October 2010, Biocon, an Indian pharmaceutical company, and Pfizer partnered to develop and market biosimilar insulin analogs (see NewNowNext in diaTribe #26). A...
At EASD, Cellnovo announced that it had received approval in Europe for its new insulin patch pump. It will be launched soon in the UK, and its submission to the FDA is...
Late last year, we found out about a new drug being developed by Reata Pharmaceuticals for the treatment of chronic kidney disease (CKD), a disorder that occurs more...
Novo Nordisk’s Head of China Ron Christie divulges details on the state of diabetes care in the world’s most populous nation.

Pages